Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of obexelimab in warm autoimmune hemolytic anemia
ISRCTN13110963Phase 3Active, not recruiting
- Sponsor
- Zenas BioPharma
- Start
- Sep 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial of obexelimab in warm autoimmune hemolytic anemia (wAIHA), sponsored by Zenas BioPharma. Started Sep 2023; status: active, not recruiting.
02
Drugs
obexelimab
03
Conditions
warm autoimmune hemolytic anemia (wAIHA)
Beyond the preview
Go deeper on ISRCTN13110963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN13110963.